Announced details
Treatment of Hunter syndrome (mucopolysaccharidosis type II), rare disease care, and management of central nervous system symptoms
On sale in Japan since May 2021
The company has entered into a sales consignment agreement with Taiba. Taiba plans to sell this product in the United Arab Emirates and other MENA countries and regions.
Headquartered in the United Arab Emirates; CEO: Saif Al Hasani. The company is responsible for the marketing, sales and distribution of orphan drugs in the MENA region. It has built relationships of trust over 20 years with clinicians, healthcare institutions and global partner companies.
Regulatory authority of the United Arab Emirates (name not disclosed)
The impact on consolidated results for the fiscal year ending March 2027 will be immaterial.
The company does not address Contract Value / Offering price.
Based on the Company's research
Mol. Ther. 2018; 26(5):1366-1374
Mol. Ther. 2021; 29(5):1853-1861
Mol Ther. 2020; 27(2):456-464
Mol Ther. 2021; 29(2):671-679
Mol Ther. 2021; 29(7):2378-2386
Int. J. Mol. Sci. 2021, Volume 22, Issue 20, 10938
| Item | Details |
|---|---|
| Names of Products / Services Covered | IZCARGO®, Pabinafusp alfa, JR-141, J-Brain Cargo® |
| Counterparty | Taiba Middle East FZ LLC |
| Counterparty overview | Headquartered in the United Arab Emirates; CEO: Saif Al Hasani. The company is responsible for the marketing, sales and distribution of orphan drugs in the MENA region. It has built relationships of trust over 20 years with clinicians, healthcare institutions and global partner companies. |
| Relationship with the Company | The company has entered into a sales consignment agreement with Taiba. Taiba plans to sell this product in the United Arab Emirates and other MENA countries and regions. |
| Applicable area | Treatment of Hunter syndrome (mucopolysaccharidosis type II), rare disease care, and management of central nervous system symptoms |
| Awarding / certifying body | Regulatory authority of the United Arab Emirates (name not disclosed) |
| Usage history | On sale in Japan since May 2021 |
| Impact on Business Performance | The impact on consolidated results for the fiscal year ending March 2027 will be immaterial. |
| Source | Based on the Company's research, Mol. Ther. 2018; 26(5):1366-1374, Mol. Ther. 2021; 29(5):1853-1861, Mol Ther. 2020; 27(2):456-464, Mol Ther. 2021; 29(2):671-679, Mol Ther. 2021; 29(7):2378-2386, Int. J. Mol. Sci. 2021, Volume 22, Issue 20, 10938 |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To pursue international expansion by leveraging the marketing authorization already obtained in Japan. While advancing the global Phase III clinical trial, the company aims to make the treatment available to patients worldwide as soon as possible.